Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.

Landgren O, Lu SX, Hultcrantz M.

Semin Hematol. 2018 Jan;55(1):44-50. doi: 10.1053/j.seminhematol.2018.03.001. Epub 2018 Mar 5. Review.

PMID:
29759154
2.

MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool.

Landgren O.

Semin Hematol. 2018 Jan;55(1):1-3. doi: 10.1053/j.seminhematol.2018.03.003. Epub 2018 Mar 15.

PMID:
29759146
3.

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.

Tageja N, Korde N, Kazandjian D, Panch S, Manasanch E, Bhutani M, Kwok M, Mailankody S, Yuan C, Stetler-Stevenson M, Leitman SF, Sportes C, Landgren O.

Bone Marrow Transplant. 2018 May 4. doi: 10.1038/s41409-018-0170-0. [Epub ahead of print]

PMID:
29728700
4.

Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.

Landgren O, Zeig-Owens R, Giricz O, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl U, Pradhan K, Hall CB, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP, Verma A, Prezant DJ.

JAMA Oncol. 2018 Jun 1;4(6):821-827. doi: 10.1001/jamaoncol.2018.0509.

PMID:
29710195
5.

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.

Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O.

Eur J Haematol. 2018 Apr 20. doi: 10.1111/ejh.13083. [Epub ahead of print] Review.

PMID:
29676004
6.

Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.

Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, Björkholm M, Kristinsson SY.

Haematologica. 2018 Mar 22. pii: haematol.2017.183475. doi: 10.3324/haematol.2017.183475. [Epub ahead of print] No abstract available.

7.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM.

Cancer Res. 2018 May 15;78(10):2747-2759. doi: 10.1158/0008-5472.CAN-17-1900. Epub 2018 Mar 20.

PMID:
29559475
8.

Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.

Gao Q, Yellapantula V, Fenelus M, Pichardo J, Wang L, Landgren O, Dogan A, Roshal M.

Mod Pathol. 2018 Jun;31(6):881-889. doi: 10.1038/s41379-018-0011-0. Epub 2018 Feb 5.

9.

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.

Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML.

Ann Intern Med. 2018 Mar 6;168(5):317-325. doi: 10.7326/M17-0028. Epub 2018 Jan 16.

PMID:
29335713
10.

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, Landau H, Korde N, Mailankody S, Smith E, Chung DJ, Koehne G, Shah GL, Alexander A, Patel M, Ballagi A, Grundberg I, Giralt SA, Landgren O.

Leuk Lymphoma. 2018 Aug;59(8):1981-1985. doi: 10.1080/10428194.2017.1403020. Epub 2018 Jan 8. No abstract available.

PMID:
29308691
11.

Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Thorsteinsdottir S, Lund SH, Lindqvist EK, Thordardottir M, Sigurdsson G, Costello R, Burton D, Steingrimsdottir H, Gudnason V, Eiriksdottir G, Siggeirsdottir K, Harris TB, Landgren O, Kristinsson SY.

Blood Adv. 2017 Dec 21;1(27):2790-2798. doi: 10.1182/bloodadvances.2017010454. eCollection 2017 Dec 26.

12.

The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

Jonsdottir G, Lund SH, Björkholm M, Turesson I, Hultcrantz M, Porwit A, Jethava YS, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 22;1(25):2392-2398. doi: 10.1182/bloodadvances.2017007930. eCollection 2017 Nov 28.

13.

Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.

Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 1;1(24):2186-2192. doi: 10.1182/bloodadvances.2017007609. eCollection 2017 Nov 14.

14.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.

Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O.

Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.

15.

MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.

Roshal M, Flores-Montero JA, Gao Q, Koeber M, Wardrope J, Durie BGM, Dogan A, Orfao A, Landgren O.

Blood Adv. 2017 May 3;1(12):728-732. doi: 10.1182/bloodadvances.2016003715. eCollection 2017 May 9.

16.

Shall we treat smoldering multiple myeloma in the near future?

Landgren O.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):194-204. doi: 10.1182/asheducation-2017.1.194. Review.

PMID:
29222256
17.

Serum protein markers of clonal heterogeneity in myeloma.

Landgren O.

Lancet Haematol. 2017 Dec;4(12):e565-e566. doi: 10.1016/S2352-3026(17)30216-8. No abstract available.

PMID:
29195600
18.

Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.

Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, Costello R, Dispenzieri A, Caporaso N, Mailankody S, Korde N, Hultcrantz M, Therneau TM, Larson DR, Cerhan JR, Rajkumar SV.

Blood Cancer J. 2017 Oct 20;7(10):e618. doi: 10.1038/bcj.2017.97.

19.

Racial/ethnic disparities: need more work!

Landgren O.

Blood. 2017 Oct 12;130(15):1685-1686. doi: 10.1182/blood-2017-08-798546. No abstract available.

20.

A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma.

Raju GK, Gurumurthi K, Domike R, Kazandjian D, Landgren O, Blumenthal GM, Farrell A, Pazdur R, Woodcock J.

Clin Pharmacol Ther. 2018 Jan;103(1):67-76. doi: 10.1002/cpt.871. Epub 2017 Nov 20. Review.

PMID:
28901535
21.

Host-related immunodeficiency in the development of multiple myeloma.

Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O.

Leuk Lymphoma. 2018 May;59(5):1127-1132. doi: 10.1080/10428194.2017.1361026. Epub 2017 Aug 9.

PMID:
28792255
22.

Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease.

Hofmann JN, Mailankody S, Korde N, Wang Y, Tageja N, Costello R, Zingone A, Hultcrantz M, Pollak MN, Purdue MP, Landgren O.

Obesity (Silver Spring). 2017 Aug;25(8):1317-1320. doi: 10.1002/oby.21894. Epub 2017 Jun 11.

23.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.

Ann Oncol. 2018 Apr 1;29(4):1074. doi: 10.1093/annonc/mdx160. No abstract available.

PMID:
28541409
24.

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.

Simmons JK, Michalowski AM, Gamache BJ, DuBois W, Patel J, Zhang K, Gary J, Zhang S, Gaikwad S, Connors D, Watson N, Leon E, Chen JQ, Kuehl WM, Lee MP, Zingone A, Landgren O, Ordentlich P, Huang J, Mock BA.

Mol Cancer Ther. 2017 Sep;16(9):2008-2021. doi: 10.1158/1535-7163.MCT-17-0171. Epub 2017 May 18.

PMID:
28522584
25.

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, Landgren O, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):217-221. doi: 10.1007/s00280-017-3323-8. Epub 2017 May 9.

PMID:
28488026
26.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

27.

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.

Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ.

Oncotarget. 2017 Apr 25;8(17):27854-27867. doi: 10.18632/oncotarget.15718.

28.

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.

Landgren O, Iskander K.

J Intern Med. 2017 Apr;281(4):365-382. doi: 10.1111/joim.12590. Epub 2017 Feb 16. Review.

PMID:
28205262
29.

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.

Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, Hieke S, Baayen C, Müller SJ, Einsele H, Sonneveld P, Landgren O, Schumacher M, Wäsch R.

Haematologica. 2017 May;102(5):910-921. doi: 10.3324/haematol.2016.162693. Epub 2017 Feb 2.

30.

New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.

Landgren O, Rajkumar SV.

Clin Cancer Res. 2016 Nov 15;22(22):5428-5433. doi: 10.1158/1078-0432.CCR-16-0866. Review.

31.

Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.

Shah GL, Landau H, Londono D, Devlin SM, Kosuri S, Lesokhin AM, Lendvai N, Hassoun H, Chung DJ, Koehne G, Jhanwar SC, Landgren O, Levine R, Giralt SA.

Leuk Lymphoma. 2017 Aug;58(8):1823-1831. doi: 10.1080/10428194.2016.1260126. Epub 2017 Jan 12.

32.
33.

A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.

Kazandjian D, Landgren O.

Semin Oncol. 2016 Dec;43(6):682-689. doi: 10.1053/j.seminoncol.2016.10.008. Epub 2016 Nov 16. Review.

34.

Proteomic profiling in plasma cell disorders: a feasibility study.

Mailankody S, Devlin SM, Korde N, Lendvai N, Lesokhin A, Landau H, Hassoun H, Ballagi A, Ekman D, Chung DJ, Patel M, Koehne G, Giralt S, Landgren O.

Leuk Lymphoma. 2017 Jul;58(7):1757-1759. doi: 10.1080/10428194.2016.1258699. Epub 2016 Dec 2. No abstract available.

35.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.

Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606. Review. Erratum in: Ann Oncol. 2017 May 24;:.

36.

Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.

Mailankody S, Landgren O.

Best Pract Res Clin Haematol. 2016 Jun;29(2):187-193. doi: 10.1016/j.beha.2016.08.015. Epub 2016 Sep 4. Review.

PMID:
27825465
37.

Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III.

Rubio-Tapia A, Ludvigsson JF, Choung RS, Brantner TL, Rajkumar SV, Landgren O, Murray JA.

BMC Gastroenterol. 2016 Nov 3;16(1):136.

38.

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Lindqvist EK, Landgren O, Lund SH, Turesson I, Hultcrantz M, Goldin L, Björkholm M, Kristinsson SY.

Ann Hematol. 2017 Feb;96(2):261-269. doi: 10.1007/s00277-016-2859-8. Epub 2016 Nov 2.

39.

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.

Manasanch EE, de Larrea CF, Zingone A, Steinberg SM, Kwok M, Tageja N, Bhutani M, Kazandjian D, Roschewski M, Wu P, Carter G, Zuchlinski D, Mulquin M, Lamping L, Costello R, Burton D, Gil LA, Figg WD, Maric I, Calvo KR, Yuan C, Stetler-Stevenson M, Korde N, Landgren O.

Leuk Lymphoma. 2017 Mar;58(3):639-645. doi: 10.1080/10428194.2016.1214953. Epub 2016 Aug 9.

PMID:
27687480
40.

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.

Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, Landgren O, Childs RW.

Clin Cancer Res. 2016 Nov 1;22(21):5211-5222. Epub 2016 Jun 15.

41.

Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.

Ogunniyi A, Rodriguez M, Devlin S, Adel N, Landau H, Chung DJ, Lendvai N, Lesokhin A, Koehne G, Mailankody S, Korde N, Reich L, Landgren O, Giralt S, Hassoun H.

Leuk Lymphoma. 2017 May;58(5):1123-1129. doi: 10.1080/10428194.2016.1239261. Epub 2016 Oct 13.

42.

MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.

Mateos MV, Landgren O.

Cancer Treat Res. 2016;169:3-12. Review.

PMID:
27696254
43.

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

Murata K, McCash SI, Carroll B, Lesokhin AM, Hassoun H, Lendvai N, Korde NS, Mailankody S, Landau HJ, Koehne G, Chung DJ, Giralt SA, Ramanathan LV, Landgren O.

Clin Biochem. 2018 Jan;51:66-71. doi: 10.1016/j.clinbiochem.2016.09.015. Epub 2016 Sep 21.

PMID:
27664535
44.

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

Landgren O, Devlin S, Boulad M, Mailankody S.

Bone Marrow Transplant. 2016 Dec;51(12):1565-1568. doi: 10.1038/bmt.2016.222. Epub 2016 Sep 5.

45.

Myeloma minimal residual disease testing in the United States: Evidence of improved standardization.

Salem D, Stetler-Stevenson M, Yuan C, Landgren O.

Am J Hematol. 2016 Dec;91(12):E502-E503. doi: 10.1002/ajh.24540. Epub 2016 Oct 11. No abstract available.

46.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H.

Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Review.

PMID:
27511158
47.

Myeloma imaging: time to move on!

Manasanch EE, Landgren O.

Leuk Lymphoma. 2016 Jul;57(7):1499-500. doi: 10.3109/10428194.2016.1143941. Epub 2016 May 5. No abstract available.

PMID:
27145898
48.

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

Lendvai N, Yee AJ, Tsakos I, Alexander A, Devlin SM, Hassoun H, Korde N, Lesokhin AM, Landau H, Mailankody S, Koehne G, Chung DJ, Landgren O, Raje NS, Giralt S.

Blood. 2016 May 12;127(19):2355-6. doi: 10.1182/blood-2016-01-694786. Epub 2016 Mar 28. No abstract available.

49.

Monoclonal gammopathy-associated pure red cell aplasia.

Korde N, Zhang Y, Loeliger K, Poon A, Simakova O, Zingone A, Costello R, Childs R, Noel P, Silver S, Kwok M, Mo C, Young N, Landgren O, Sloand E, Maric I.

Br J Haematol. 2016 Jun;173(6):876-83. doi: 10.1111/bjh.14012. Epub 2016 Mar 21.

50.

Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study.

Kjellander C, Björkholm M, Källman O, Giske CG, Weibull CE, Löve TJ, Landgren O, Kristinsson SY.

Ann Hematol. 2016 May;95(6):871-9. doi: 10.1007/s00277-016-2643-9. Epub 2016 Mar 15.

PMID:
26976017

Supplemental Content

Loading ...
Support Center